To see the other types of publications on this topic, follow the link: GSRS (Gastrointestinal Symptom Rating Scale).
Journal articles on the topic 'GSRS (Gastrointestinal Symptom Rating Scale)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'GSRS (Gastrointestinal Symptom Rating Scale).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Singh, Sunita, Niraj K. Srivastava, Rahul Yadav, et al. "Acute gastrointestinal and post-acute COVID-19 gastrointestinal syndrome assessment on the Gastrointestinal Symptom Rating Scale scoring system: A questionnaire-based survey." Journal of Family Medicine and Primary Care 13, no. 12 (2024): 5787–98. https://doi.org/10.4103/jfmpc.jfmpc_707_24.
Full textAbstract:
ABSTRACT Background: Post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) is the persistence of sequel of acute SARS-COV-2 infection. Persistent/acquired gastrointestinal symptoms (GI-PACS) include loss of appetite, nausea, weight loss, abdominal pain, heartburn, dysphagia, altered bowel motility, dyspepsia, and irritable bowel syndrome. The study aimed to assess the short- and long-term GI-PACS syndrome on the GSRS scale. Methods: A cross-sectional, retrospective record analysis and telephonic questionnaire-based survey were conducted at a tertiary referral center in northern India. The data incorporated patients treated from April 2021 to March 2023. Exclusion criteria were neurological disorders, dementia, inability to understand Hindi/English languages, and psychiatric problems. All patients who met the inclusion criteria were telephonically called from November 2023 to January 2024. Results: The study population was 350 recovered patients from SARS-COVID-19 illness. Forty-three responses were removed during data cleaning and removal of duplication. The data analysis of 307 participants (ICU admissions=92, non-ICU admissions=123, and outdoor treatment =92) was done. The proportion of patients not having any GI symptoms, having at least one GI symptom, and having more than one GI symptom before SARS-COV-2 illness was 3%(3/307), 4.9% (15/307), and 3.6% (11/307), respectively. The four major GI symptoms analyzed in the study were vomiting, pain in the abdomen, diarrhea, and constipation. Overall, 13% (40/307) of the study population did not have any major GI symptoms before SARS-COV-2 diseases. During acute SARS-COV-2 illness, 86.97% (267/307) of patients develop new GI symptoms. Post SARS-COV-2 illness, the overall mean GSRS score for 15 items was 2.14 ± 0.829. The acquired GI-PACS was abdominal pain syndrome (mean score 2.5190 ± SD 0.86650), constipation syndrome (mean score 2.3844 ± 0.83840), reflux syndrome (mean score 2.2866 ± 1.31889), indigestion syndrome (mean score 1.8591 ± 0.93076), and diarrhea syndrome (mean score 1.8122 ± 0.90899). Overall, fever (95.1%, P = 0.007), anosmia (45.0%, P = 0.042), cough (80.1%, P = 0.032), and hospitalization (30.0%, P = 0.003) had a more significant association with one of the major four GI symptoms during the acute phase of SARS-COV-2 illness. Home-isolated patients having loss of appetite (95.4%, P = 0.0001) had a significant association with one of the major four GI symptoms during the acute phase of SARS-COV-2 illness. Hospitalized patients having fever (80.7%, P = 0.031), breathlessness (83.8%, P = 0.003), loss of smell (97.0%, P = 0.001), and cough (82.7%, P = 0.048) had a more significant association with one of the major four GI symptoms during the acute SARS-COV-2 illness. Abdominal pain, reflux, and constipation were considered severe GI symptoms (symptom GSRS score greater than total mean GSRS score). Diarrhea and indigestion were considered mild symptoms (symptom GSRS score was less than the total mean GSRS score). The GI symptoms during acute SARS-COV-2 illness recovered in 66.1% (203/307) patients within 3 months. The respondents taking medicines for more than 1 year following SARS-COV-2 illness were 19.2%. 12.0% (37/307) of respondents suffered from persistent GI symptoms on a mean follow-up of 20.1 ± 0.82 months. Conclusion: Long-term COVID-19 syndrome frequently manifested as GI symptoms, whereas most symptoms subsided with time.
2
Bae, Kwang-Ho, Ki-Hyun Park, Siwoo Lee, Ilkoo Ahn, Do-hyeon Kim, and Kyung-hwan Kong. "Association Between Cold Hypersensitivity in the Hands and Feet and Gastrointestinal Symptoms: Findings in a Community-Based Cohort Study." Journal of Internal Korean Medicine 45, no. 6 (2024): 1207–25. https://doi.org/10.22246/jikm.2024.45.6.1207.
Full textAbstract:
Objective: This study aimed to analyze whether cold hypersensitivity in the hands and feet (CHHF) was associated with gastrointestinal symptoms and whether changes in CHHF were linked to the emergence of new gastrointestinal symptoms.Methods: Data were collected from 5,476 participants in a community-based cohort two or three times between 2009 and 2015. Participants provided information on CHHF, gastrointestinal symptoms (Nepean Dyspepsia Index (NDI), Gastrointestinal Symptom Rating Scale (GSRS), and ordinary symptoms questionnaires about the upper gastrointestinal tract and lower gastrointestinal tract (OSUG, OSLG).Results: At baseline, 34.1% of the subjects had CHHF, and 79.4% maintained the same status at follow-up. CHHF was associated with significantly higher NDI and GSRS and lower OSUG and OSLG scores. In addition, CHHF was associated with an increased prevalence of gastrointestinal dysfunction, as defined by the bottom 25% of the OSUG and OSLG scores. Newly developed gastrointestinal dysfunction was also more common in those with persistent CHHF or in those who developed CHHF.Conclusion: CHHF was associated with increased gastrointestinal symptoms.
3
J Soman, Raunak, Kiranjit Singh, and Malisetty Venkat Swamy. "Efficacy and Safety of Probiotic Bacillus coagulans-SNZ 1969 in Gastrointestinal Discomfort: A Randomized, Placebo-Controlled Study." International Journal of Health Sciences and Research 12, no. 3 (2022): 253–64. http://dx.doi.org/10.52403/ijhsr.20220336.
Full textAbstract:
Purpose: Bacillus coagulans-based probiotics restore gut microbiota and alleviate symptoms of gastrointestinal (GI) discomfort. This study evaluated the efficacy and safety of SNZ 1969 in individuals with GI discomfort. Methods: This was a single-center, randomized, placebo-controlled, parallel‑arm, double-blind study. Participants with GI discomfort (n=30 in each arm) without a specific pathology were randomized to receive B. coagulans‑SNZ 1969, TriBac, or placebo, once daily after a major meal, for 30 days. Symptoms were assessed using the Severity of Dyspepsia Assessment (SODA) scale, Gastrointestinal Symptom Rating Scale (GSRS), and Short Form 36 (SF-36) at baseline, day 15, day 30, and 7 days after the end of treatment. Results: A total of 29 participants from SNZ 1969 and 28 from the placebo group completed the study. Treatment with SNZ 1969 significantly improved the total SODA score (18.34 ± 5.35 vs. 12.60 ± 4.79; p < 0.001), SODA subscores for pain intensity (15.41 ± 4.98 vs. 10.71 ± 3.68; p < 0.001), nonpain symptoms (7.28 ± 2.23 vs. 4.89 ± 2.94; p < 0.001), satisfaction (−4.43 ± 1.81 vs. −3.00 ± 1.22; p = 0.002), and symptom of sour taste (1.52 ± 0.78 vs. 0.75 ± 0.89; p = 0.001) compared with placebo and were consistent after 7 days of treatment discontinuation (p < 0.05). No significant score reduction was observed for GSRS compared with placebo. Two adverse events, fever and cold, were unrelated to SNZ 1969. Conclusion: SNZ 1969 was found to be safe and effective in reducing GI discomfort, especially dyspepsia. Key words: Bacillus coagulans, Gastrointestinal discomfort, Gastrointestinal Symptom Rating Scale, Probiotic, SNZ 1969, Severity of Dyspepsia Assessment scale.
4
SOUZA, Gabriela Santos, Fabiana Andrea Hoffmann SARDÁ, Eliana Bistriche GIUNTINI, Iara GUMBREVICIUS, Mauro Batista de MORAIS, and Elizabete Wenzel de MENEZES. "TRANSLATION AND VALIDATION OF THE BRAZILIAN PORTUGUESE VERSION OF THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS) QUESTIONNAIRE." Arquivos de Gastroenterologia 53, no. 3 (2016): 146–51. http://dx.doi.org/10.1590/s0004-28032016000300005.
Full textAbstract:
ABSTRACT Background - Bowel function is a widely evaluated parameter in interventional and longitudinal studies since it is associated with good maintenance of health. The evaluation of intestinal function has been performed by many questionnaires, however, there are few options validated in Brazilian Portuguese. Objective - The aim of this work was to translate and validate into Brazilian Portuguese the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. Methods - Translation and cultural adaptation were performed according to a previously established methodology followed by reliability calculations. Results - The final translated GSRS questionnaire showed an adequate value of overall reliability of Cronbach's alpha of 0.83, and its domains were classified from acceptable to adequate. The overall test-retest reliability by intraclass correlation coefficient (ICC) was 0.84, considered excellent. Conclusion - The GSRS was translated and validated into Brazilian Portuguese, with appropriate internal consistency and reliability and is available to be used in assessments of bowel function.
5
Kim, Hakkyeom, Jiyoon Park, Jiseong Moon, et al. "A Case Report on Korean Medical Treatment for a Patient with Chronic Nausea and Vomiting Syndrome." Journal of Internal Korean Medicine 42, no. 5 (2021): 967–75. http://dx.doi.org/10.22246/jikm.2021.42.5.967.
Full textAbstract:
This study investigated the case of a nineteen-year-old female patient with chronic nausea, vomiting, and abdominal distension, who was diagnosed with CNVS and Spleen-Qi deficiency. Subjective symptoms were recorded with the Numerical Rating Scale (NRS) every morning, and the Gastrointestinal Symptom Rating Scale (GSRS) was used on the days of admission and discharge. For eleven days following admission, she took <i>Bojungikki-tang-gagam</i> and received acupuncture and moxibustion therapy. After three days of treatment, her nausea and vomiting ceased, and abdominal distension improved from NRS 3 to 0 after seven days of treatment. The GSRS score for the specific symptoms improved from 3 to 2; however, the total score remained largely unchanged (from 20 to 21). This case suggests that Korean medical treatment may improve CNVS.
6
Parijs, Betsy Abraham-Van, Mark Price, Francisco Leon, and Sheri Fehnel. "Relevance of the Gastrointestinal Symptom Rating Scale (Gsrs) in Patients with Celiac Disease." American Journal of Gastroenterology 103 (September 2008): S395. http://dx.doi.org/10.14309/00000434-200809001-01009.
Full text
7
Mestrovic, Antonio, Josko Bozic, Katarina Vukojevic, and Ante Tonkic. "Impact of Different Helicobacter pylori Eradication Therapies on Gastrointestinal Symptoms." Medicina 57, no. 8 (2021): 803. http://dx.doi.org/10.3390/medicina57080803.
Full textAbstract:
Background and Objectives: Helicobacter pylori (H. pylori) infection impairs quality of life. However, whether eradication therapy ameliorates gastrointestinal symptoms remains questionable. The main objective of this study was to evaluate the influence of H. pylori eradication therapy on gastrointestinal symptoms. Materials and Methods: A total of 140 patients, 59 women and 81 men, with a mean age of 61 and suffering from H. pylori infection in the University Hospital of Split, Croatia, were enrolled in the study. Patients were randomly assigned to either concomitant or hybrid therapies. The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was completed by patients prior to and after the eradication therapy. Results: In both groups, the total GSRS score improved significantly after therapy. In the concomitant group, the abdominal pain score, reflux symptoms score and indigestion score decreased significantly after therapy. In the group with hybrid therapy, all five groups of symptoms (abdominal pain, reflux symptoms, indigestion, diarrhea and constipation) significantly decreased after therapy. Patients with adverse events had significantly higher total GSRS scores after eradication therapy. Conclusions: H. pylori eradication therapy could alleviate gastrointestinal symptoms regardless of the treatment used, but the favorable effect seemed to be more pronounced after hybrid therapy.
8
Shin, Seon Mi, Sang Jun Youn, Yong Choi, et al. "Fermented Gold Kiwi for Improved Gastric Health: Evaluation of Efficacy and Safety in a Randomised, Double-Blind, Placebo-Controlled Trial." Nutrients 16, no. 16 (2024): 2670. http://dx.doi.org/10.3390/nu16162670.
Full textAbstract:
This randomised double-blind placebo-controlled trial evaluated the efficacy and safety of fermented gold kiwi (FGK) in improving gastrointestinal health. A total of 100 participants were enrolled and randomly assigned to treatment or placebo groups. Over 8 weeks, the participants consumed an FGK or placebo preparation daily. Primary outcomes included changes in gastrointestinal symptoms assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and the Korean version of the Nepean Dyspepsia Index (NDI-K), as well as quality of life assessed using the Functional Dyspepsia-related Quality of Life questionnaire. The FGK group showed significant improvements in GSRS and NDI-K total and subdomain scores compared with the placebo group. Moreover, the quality of life scores were significantly better in the FGK group than in the placebo group. Safety evaluations revealed no significant adverse events or clinically meaningful changes upon assessing laboratory test results. This study demonstrated that FGK is a safe and effective dietary supplement for improving gastrointestinal health in adults with gastrointestinal symptoms.
9
Wilder-Smith, Clive H., Andrea Materna, and Søren S. Olesen. "Blueberries Improve Abdominal Symptoms, Well-Being and Functioning in Patients with Functional Gastrointestinal Disorders." Nutrients 15, no. 10 (2023): 2396. http://dx.doi.org/10.3390/nu15102396.
Full textAbstract:
Blueberries beneficially modulate physiologic mechanisms relevant to the pathogenesis of functional gastrointestinal disorders (FGID). Forty-three patients with FGID received freeze-dried blueberries (equivalent to 180 g fresh blueberries) or sugar and energy-matched placebo in a double-blind, randomized, cross-over study. After 6 weeks of treatment, the differences in Gastrointestinal Clinical Rating Scale (GSRS) scores and abdominal symptom relief were compared as primary outcome measures. The quality of life and life functioning ratings (OQ45.2 questionnaire), Bristol stool scales, and fructose breath test results constituted secondary outcome measures. Blueberry treatment resulted in more patients with relevant abdominal symptom relief compared to placebo (53% vs. 30%, p = 0.03). Total and pain GSRS scores improved insignificantly (mean treatment differences [95% CI]: −3.4 [−7.4 to 0.6] (p = 0.09) and −1.0 [−2.2 to 0.1] (p = 0.08), respectively). OQ45.2 scores improved during blueberry treatment compared to placebo (treatment difference −3.2 [95% CI: −5.6 to −0], p = 0.01). Treatment effect differences for the further measures did not reach statistical significance. Blueberries relieved abdominal symptoms and improved general markers of well-being, quality of life, and life functioning more than placebo in patients with FGID. Consequently, the polyphenol and fiber components of blueberries exert broad beneficial effects separate from the sugars present in both treatments.
10
Altinsoy, Canan, and Derya Dikmen. "How Are Brain Fog Symptoms Related to Diet, Sleep, Mood and Gastrointestinal Health? A Cross-Sectional Study." Medicina 61, no. 2 (2025): 344. https://doi.org/10.3390/medicina61020344.
Full textAbstract:
Background and Objectives: Brain fog, characterized by cognitive difficulties such as memory impairment, lack of focus, and mental fatigue, is a common symptom reported during recovery from COVID-19, particularly in long COVID cases. This study explores potential triggers such as sleep quality, mood, and gastrointestinal health and examines the link between adherence to the MIND diet and brain fog severity. Materials and Methods: A cross-sectional study was conducted between 1 July and 15 December 2022. The questionnaire assessed brain fog symptoms, dietary habits, sleep quality, mood, and gastrointestinal symptoms. Linear regression analysis examined the relationships between brain fog symptoms, demographic factors, sleep quality, MIND diet adherence, and gastrointestinal symptoms. Results: Brain Fog Scale (BFS) scores were significantly higher in individuals who had COVID-19 (p < 0.05) and even higher in those with reinfection. Women had higher BFS and Brain Fog Severity Score (BFSS), MIND Diet, The Gastrointestinal Symptom Rating Scale (GSRS), Brief Mood Introspection Scale (BMIS) Pleasant-Unpleasant scores (p < 0.05). BFS and BFSS were positively correlated with GSRS (p < 0.05), while no correlation was found with MIND diet adherence. A negative correlation was observed between BFS and Sleep Quality Scale (SQS) (p < 0.05), but this was not significant in regression (p = 0.367). GSRS, Pleasant–Unpleasant Dimension, and Arousal–Calm Dimension were significant predictors of BFS (R = 0.599, R2 = 0.358, p < 0.01). Conclusions: This study identifies being female as a risk factor for brain fog symptoms, with women reporting higher BFS and BFSS scores. While sleep quality showed a negative correlation with brain fog symptoms, this relationship was not significant in the regression model, suggesting that other factors, such as mood and gastrointestinal symptoms, may play a more dominant role. However, adherence to the MIND diet showed no significant relationship with brain fog symptoms. These findings suggest that addressing mood and gastrointestinal health may be key to managing brain fog in long COVID.
11
Sim, Yoohyun, Nahyun Jeong, Dahee Jeong, et al. "Case Report: Traditional Korean Medical Treatment for Slow Transit Constipation Diagnosed as Colonic Inertia in a Laxative-Dependent Patient." Journal of Internal Korean Medicine 46, no. 2 (2025): 199–209. https://doi.org/10.22246/jikm.2025.46.2.199.
Full textAbstract:
Objective: This case study reports on the effectiveness of traditional Korean medicine in treating slow transit constipation (STC) and colonic inertia.Methods: A 68-year-old male patient diagnosed with STC and colonic inertia received inpatient Korean medical treatments, including acupuncture, electroacupuncture, herbal medicine, and moxibustion, for approximately seven weeks. Changes in symptoms were evaluated using the Numeric Rating Scale (NRS) and the Gastrointestinal Symptom Rating Scale (GSRS), while quality of life was evaluated using the EuroQol-5 Dimension-5 Level (EQ-5D-5L) and the EuroQol Visual Analog Scale (EQ-VAS).Results: After treatment, the patient showed significant improvement in constipation-related symptoms and quality of life. The NRS score for constipation-related discomfort decreased from 8 to 1, and the score for dyspepsia decreased from 5 to 0. The GSRS score improved from 23 to 16, indicating a reduction in gastrointestinal symptoms. The EQ-VAS score increased from 50 to 90 and the EQ-5D-5L index improved from 0.722 to 0.886, reflecting an improved quality of life. In addition, bowel movement frequency and stool consistency normalized without the need for laxatives.Conclusion: This study suggests that Korean medical treatment, including acupuncture, electroacupuncture, herbal medicine, and moxibustion, may be an effective therapeutic approach for patients with slow transit constipation and colonic inertia.
12
Sitharthan, R. "Evaluating Action of Homoeopathy by using Gastrointestinal Symptom Rating Scale (GSRS) in Gastro Intestinal Disorders- A Case Series." Advancements in Homeopathic Research 7, no. 4 (2022): 29–37. http://dx.doi.org/10.48165/ahr.2022.7.4.2.
Full textAbstract:
Gastrointestinal disorders are the one of the attention seeking conditions in day to day life which affects 10- 15% of total population. Gastrointestinal Symptom Rating Scale (GSRS) is a tool used to measure the severity and gradation of dyspepsia. Infections, gastrointestinal motor abnormalities, brain-gut interaction, visceral hypersensitivity, inflammation, central neural dysregulation, altered gut flora are main reasons for gastrointestinal disorders. Common presentations of gastro intestinal disorders are nausea, vomiting, heart burn, dyspepsia, pain abdomen, flatulency, bowel movement alteration (constipation, diarrhoea) and bleeding per rectum.Homoeopathy is asystem of medicine which is based on “Similia Similibus Curentur” and with the combination of constitutional prescription and law of similars the normal harmonious health will be maintained in all the patients.
13
Jang, Hye-yeon, Sang-gu Yu, Do-hyeong Kim, and Young-su Lee. "A Case Report on a Fibromyalgia Patient with Gastrointestinal Symptoms Treated with Odu-tang." Journal of Internal Korean Medicine 42, no. 5 (2021): 863–71. http://dx.doi.org/10.22246/jikm.2021.42.5.863.
Full textAbstract:
Objective: The purpose of this study was to investigate the effects of Korean medical treatment on a fibromyalgia patient with gastrointestinal symptoms, using herbal medicines selected according to new rather than existing standards.Method: A 52-year-old female patient with fibromyalgia was treated with <i>Odu-tang</i> and acupuncture, cupping, and moxibustion for 22 days. To evaluate the treatment, we used the Numerical Rating Scale (NRS), American College of Rheumatology’s Preliminary Diagnostic Criteria (ACR), and Korean Gastrointestinal Symptom Rating Scale (KGSRS).Result: Following treatment, pantalgia diminished, NRS, and ACR scores improved, and the GSRS score decreased from 29 to 11.Conclusion: This study suggests that Korean medical treatment could effectively reduce pain and improve digestive symptoms in patients with fibromyalgia. It also presents a new method that considers individual characteristics when choosing herbal medicine.
14
Qaiser, Muhammad Affan, Batool Butt, Farooq Ahmed, Neha Niaz, Niaz Ahmed, and Ghulam Muhammad. "Comparing Hemodialysis and Peritoneal Dialysis Patients for Gastrointestinal Symptoms." Pakistan Journal of Medical and Health Sciences 17, no. 3 (2023): 347–49. http://dx.doi.org/10.53350/pjmhs2023173347.
Full textAbstract:
Objective: The purpose of this research was to compare gastrointestinal (GI) symptoms in ESRD patients receiving PD and HD to see whether there were any significant changes. Methods: After the ethical approval from the institute review board, this crossectional study was conducted at shahida Islam medical complex ,lodhran. From 01/01/22 to 30/06/22. A modified 15-item gastrointestinal symptom rating scale (GSRS) questionnaire was used to assess GI symptoms; this questionnaire included questions on eating dysfunction. Age, a etiology of ESRD, and most recent adequacy evaluation of dialysis were collected through the follow-up database, patient interviews, and chart reviews. Results: Total seventy patients were included in the present study, N=35 was on hemodialysis and N=35 on peritoneal dialysis. HD and PD patients were similar with respect to age, sex, the occurrence of diabetes mellitus, and average dialysis duration. In ESRD patients’ overall prevalence of GI symptoms (GSRS >1) was 68.5% (48/70 patients). Patients with a GSRS > 1 were more common among those with HD group (28/35; 80%) than those with PD (57%; 20/35) (P 0.058*). In the HD group, more patients suffered from abdominal pain, constipation, and diarrhea (74%, 60% and 68.5%, respectively), compared with those in the PD group (34%, 28.5% and 32%, respectively; P value is 0.003, 0.001, and 0.008 respectively) Conclusion: Gastrointestinal (GI) symptoms vary in frequency, intensity, and variety across HD and PD individuals. Keywords: Gastrointestinal symptom, Hemodialysis, Peritoneal dialysis, End-stage renal disease
15
Kenna, Jade E., Megan C. Bakeberg, Maddison Y. Abonnel, Frank L. Mastaglia, and Ryan S. Anderton. "Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson’s Disease Cohort." Parkinson's Disease 2022 (November 25, 2022): 1–8. http://dx.doi.org/10.1155/2022/4053665.
Full textAbstract:
Background. Gastrointestinal symptoms (GIS) in people with Parkinson’s disease (PwP) are often underreported and may remain untreated. Constipation is a common nonmotor symptom that can adversely affect health-related quality of life (QoL); however, the impact of other GIS has not been adequately investigated. Objectives. To investigate the relationship between QoL and constipation using the Bristol Stool Chart, bowel movement frequency, and a perceived constipation measure; and to explore the relationship between QoL and other GIS in an Australian PD cohort. Methods. The impact of constipation and other GIS on QoL, as measured using the PDQ-39 scale, was assessed in a cohort of 144 (89 males, 55 females) clinic-attending PwP. Constipation was assessed using the Bristol Stool Chart as well as a composite constipation measure, and the Gastrointestinal Symptom Rating Scale (GSRS) was used to rate other GIS. Covariate corrected linear regression models were utilised to determine significant associations between GIS and QoL scores. Results. Individual and combined constipation measures were significantly associated with poorer QoL ( p = 0.032 and p = 0.002 , respectively). Analysis of GSRS symptom domains showed that in addition to symptoms of gastrointestinal hypomotility, a number of other symptoms such as increased eructation and increased flatus were also associated with poorer QoL. Conclusions. The findings point to the importance of GIS as contributor to health-related QoL in PwP. A better understanding of the relationship between GIS and QoL will help facilitate the development of more effective screening and treatment programs to improve symptom management and QoL for PwP.
16
Pacheco, Gabriella, Andreza Ketly da Silva Araújo, André Luis Fernandes Lopes, et al. "Pharmacological therapy with azithromycin, hydroxychloroquine and ivermectin increased gastrointestinal side effects in a population in northeast Brazil." Peer Review 6, no. 3 (2024): 156–69. http://dx.doi.org/10.53660/prw-1807-3432.
Full textAbstract:
O surgimento da pandemia de COVID-19 impulsionou o consumo de combinações de medicamentos como o Kit COVID Brasileiro composto por azitromicina, hidroxicloroquina e ivermectina. Os efeitos dessas drogas no trato gastrointestinal permanecem incertos, motivando este estudo. Foi realizado um estudo epidemiológico transversal analítico e quantitativo em pacientes (n=124) da macrorregião costeira do estado do Piauí, Brasil, com diagnóstico confirmado de COVID-19, no período de fevereiro e agosto de 2021. Os sintomas gastrointestinais foram avaliados por meio do questionário Gastrointestinal Symptom Rating Scale (GSRS). A renda mostrou-se um fator na escolha do tratamento. Entre os 15 domínios do GSRS, os escores de dor abdominal, dor de fome, diarreia e urgência defecar foram significativamente maiores (p<0,05) no grupo de tratamento do que no grupo não tratado. Em relação às síndromes avaliadas, apenas as síndromes diarreicas apresentaram diferença significativa de frequência entre os grupos. O uso de medicamentos do Kit COVID associado ao desenvolvimento de sintomas gastrointestinais destaca a importância de considerar os potenciais efeitos adversos dos medicamentos em pacientes diagnosticados com COVID-19.
17
Min, Baek Ki, Joon Soo Jin, Do Eun Lee, Won Bin Shin, Jin Hyeon Shin, and In Ae Youn. "The Effect of Complex Korean Medical Treatment with Acupotomy on Irritable Bowel Syndrome: A Case Report." Journal of Acupuncture Research 37, no. 1 (2020): 59–63. http://dx.doi.org/10.13045/jar.2019.00311.
Full textAbstract:
The effects of complex Korean medicine treatment including acupotomy, on irritable bowel syndrome (IBS) are reported in this case study. A 54-year-old woman with diarrheal symptoms that alternatively improved and worsened for many years and worsening abdominal pain visited the emergency room and was diagnosed with IBS; she was admitted for approximately 2 weeks at the Acupuncture and Moxibustion Department of National Medical Center (NMC). Numerical rating scale (NRS), irritable bowel syndrome?quality of life (IBS-QOL), and gastrointestinal symptom rating scale (GSRS) scores were evaluated on the day of hospitalization, midway through the hospitalization period, and on the day of discharge. Abdominal pain was measured daily using NRS, and the score decreased from 8 at admission to 0 at discharge. The IBS-QOL percentile score improved from 42 points to 100 points. The total GSRS score also improved, from 30 points to 2 points. These results suggest that complex Korean medicine treatment with acupotomy, is useful for treating internal diseases, such as IBS, as well as musculoskeletal disorders.
18
Eka Arum Cahyaning Putri, Muhammad Naufal Razzan Maghribi, Muhammad Nabiel Firdausi, et al. "Comparison of gastrointestinal disorder symptoms based on the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire in second and fifth-year medical students." World Journal of Advanced Research and Reviews 26, no. 1 (2025): 2218–22. https://doi.org/10.30574/wjarr.2025.26.1.1288.
Full textAbstract:
In responding to various situations in their daily academic environment, medical students are not free from complaints or symptoms of disorders in their respective gastrointestinal systems. Medical students in particular have a tighter lecture and practicum schedule than students in other majors. This is prone to having an impact on other health statuses and even their performance achievements. If this is not handled properly, it is feared that it will have a serious impact on their careers as doctors in the future. The reason of this ponder was to decide the comparison of side effects of gastrointestinal disarranges in second and fifth-year medical students. After that, it can be used to prevent and minimize symptoms of gastrointestinal disorders in medical students so as to provide a smooth educational process until they graduate as doctors. This research method is quantitative, comparing gastrointestinal symptoms to the level of study years as a medical student using GSRS questionnaire. The respondents of the study were 77 people with purposive-non-random-sampling data collection. The data obtained were analyzed using the independent sample Z test. The comes about of the consider appeared that the normal in the second-year student group (2.10 ± 0.96) was higher than the fifth-year student group (1.90 ± 0.92) and the significance was 0.366 (p>0.05). This shows that there is no significant difference between the symptoms of gastrointestinal disorders in second and fifth-year medical students.
19
Shklyaev, A. E., D. D. Kazarin, and Yu V. Gorbunov. "Predictive capabilities of the Gastrointestinal Symptom Rating Scale in the eradication of Helicobacter pylori in patients with type 2 diabetes mellitus." JOURNAL of SIBERIAN MEDICAL SCIENCES, no. 2 (2021): 49–55. http://dx.doi.org/10.31549/2542-1174-2021-2-49-55.
Full textAbstract:
The study aimed to determine the predictive capabilities of the Gastrointestinal Symptom Rating Scale (GSRS) for assessing the effectiveness of eradication therapy in Helicobacter pylori (HP) infected patients with type 2 diabetes mellitus. The study involved 60 patients of both sexes with a diagnosis of type 2 diabetes mellitus and chronic HP-associated gastritis, the average age of patients was 61.9 years, average duration of type 2 diabetes was 10.1 years. For statistical analysis of the data, we used the method of constructing ROC curves, which allowed us to identify prognostic factors (in this case, gastroenterological syndromes, such as abdominal pain, refl ux, indigestion, diarrhea and constipation) that influence the effectiveness of eradication therapy in patients with type 2 diabetes. It was found that high values of refl ux and indigestion syndromes scales of the GSRS are associated with the probability of low eradication therapy response in patients with type 2 diabetes, i.e. these syndromes can act as complicating factors for the elimination of Helicobacter pylori. The obtained data suggest the need for screening diagnostics of Helicobacter pylori, clinical manifestations of gastrointestinal pathology and subsequent etiological and pathogenetic treatment.
20
Komleva, N., V. Dolich, I. Zaikina, A. Danilov, A. Chekhonatskiy, and D. Suyetenkov. "Risk factors for the development of digestive system diseases and prevalence of gastrointestinal symptoms in adolescents." Sanitarnyj vrač (Sanitary Inspector), no. 1 (January 1, 2020): 41–47. http://dx.doi.org/10.33920/med-08-2001-05.
Full textAbstract:
Digestive diseases are a very common pathology in children and adolescents. Analysis of risk factors for the development of diseases of the digestive system and prevalence of gastrointestinal symptoms in students of professional educational organizations are presented in the article. 265 students of vocational education organizations aged 15 to 18 years were examined. The study design was a one-time cross-sectional study (active screening). Standardized formalized maps were used (complaints, medical history, physical examination results, regime and nature of diets, lifestyle and social and economic aspects were studied) to assess frequency of gastrointestinal symptoms. Gastrointestinal Symptom Rating Scale (GSRS) – an internationally validated questionnaire for the study of quality of life developed by the Hassle Company (division of Astra) – was used to study gastrointestinal symptoms. Statistical data processing was carried out using «MS Excel 2002» program. The study was conducted in accordance with the requirements of bioethics, after receiving informed consent of adolescents and their parents. A number of adolescents who previously have been diagnosed with diseases of the digestive system are found; gastrointestinal symptoms are systematized and analyzed (symptom group according to the scales abdominal pain, reflux, dyspepsia diarrhoea, constipation) using the GSRS questionnaire; main risk factors for the development of digestive system diseases characteristic of adolescents are studied: (the nature and regime of diet, smoking, consumption of alcohol), awareness of students about the main factors of a healthy lifestyle were examined as results of the study. The results of the study must be taken into account when developing and implementing preventive and hygiene and educational measures that are aimed at maintaining health and improving the quality of life of the population and require an interdisciplinary approach.
21
Hasanzamani, Boshra, Arezoo Naderzadeh, Maryam Miri, and Mitra Ahadi. "Gastrointestinal symptoms in patients undergoing peritoneal dialysis." Journal of Renal Injury Prevention 9, no. 4 (2020): e31-e31. http://dx.doi.org/10.34172/jrip.2020.31.
Full textAbstract:
Introduction: Gastrointestinal problems are common complications in the general population and also in end-stage renal disease. Such complications could be the result of increased serum urea, dialysis effect, intraperitoneal dialysis volume or any change in individual lifestyle and medications. Objectives: The present study has focused on the prevalence of common gastrointestinal disorders among patients undergoing peritoneal dialysis. Patients and Methods: This cross-sectional study conducted in three educational hospitals of Mashhad, Iran during one year. Patients who underwent peritoneal dialysis for at least three months enrolled in the study and filled Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. Additionally, in the present study addiction has been defined as using any addictive substances including tobacco and opioids. The relationship between addiction and gastrointestinal symptoms was also investigated. Results: Among 71 patients undergoing peritoneal dialysis, most of them were male (53.5%) with mean ± SD age of 48.15±16.62 years. The mean dialysis duration was six months and the maximum duration was 13 years (mean ± SD of 2.75±2.49 years). Among 15 domains of GSRS, only abdominal distention was significantly different before and after dialysis (P=0.025). Among the gastrointestinal symptoms, only increased flatus was associated with patients’ gender (P=0.04). Addicted individuals were 15.5% among study population. Heartburn sensation, acid regurgitation, sucking sensation in epigastrium, abdominal flatus and abdominal distention were significantly related to addiction (P=0.01, P=0.005, P=0.01, P=0.009 and P=0.016, respectively). Conclusion: Only abdominal distension had been affected by peritoneal dialysis according to GSRS. Additionally, addiction of patients had great effect on some gastrointestinal problems. This finding suggests the possible effect of managing addiction in patients undergoing peritoneal dialysis to reduce gastrointestinal symptoms.
22
GALIKHANOVA, YULIA I., ALEXEY E. SHKLYAEV, ANGELINA S. PANTYUKHINA, VALERY M. DUDAREV, and DANIIL D. KAZARIN. "IMPACT OF ELECTRONIC CIGARETTES ON ACID-FORMING AND MOTOR FUNCTIONS OF THE STOMACH." Bulletin of Contemporary Clinical Medicine 16, no. 6 (2023): 14–18. http://dx.doi.org/10.20969/vskm.2023.16(6).14-18.
Full textAbstract:
Abstract. Introduction. Currently, the use of electronic cigarettes is becoming the most popular with and widespread among young people. In Russia, one third of electronic cigarettes consumers are people aged 18 to 29 years. The impact of vaping on various body organs and systems is still understudied now. The aim of our study is to investigate the acid-forming and motor functions of the stomach in people consuming electronic cigarettes. Materials and methods. The study involved 54 people, of which 27 were consumers of electronic cigarettes, all without any diagnosed organic diseases in their digestive systems. The severity of gastroenterological symptoms was assessed using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire, while motor and acid-forming functions of the stomach were assessed according to pH-impedance measurements. The findings were processed statistically using nonparametric tests with the Microsoft Office Excel 2013 and Statistica 10.0 computer programs. Results and discussions. Vaping participants had significantly more gastrointestinal symptoms according to the Gastrointestinal Symptom Rating Scale as compared to their non-smoking peers. In the group of subjects consuming electronic cigarettes, there was a greater number of pathological gastroesophageal refluxes and increased acidity in the lower esophagus and stomach as compared to the control group. Conclusions. Our findings indicate the adverse effects provided by electronic cigarettes on the functional activity of the upper gastrointestinal tract.
23
Jeong, Dahee, Chae-Rim Yoon, Su-Hyun Choi, et al. "A Case Report of Korean Medical Treatment for an Adult with Cyclic Vomiting Syndrome Analyzed by Electrogastrography and Subjective Evaluation Scale." Journal of Internal Korean Medicine 45, no. 3 (2024): 519–31. http://dx.doi.org/10.22246/jikm.2024.45.3.519.
Full textAbstract:
Objectives: This case study reports the effectiveness of Korean medical treatment in a patient with cyclic vomiting syndrome.Methods: A 29-year-old female Korean patient with cyclic vomiting syndrome received acupuncture, electroacupuncture, herbal medicine, and moxibustion for 2 weeks in hospital. Changes in symptoms were evaluated using the Gastrointestinal Symptom Rating Scale (GSRS), Visual Analog Scale (VAS), Index for Nausea, Vomiting, and Retching (INVR), Nausea Severity Scale (NSS), Nepean Dyspepsia Index-Korean version (NDI-K), quality of life using the Functional Dyspepsia Related Quality of Life questionnaire (FD-QoL), and gastric motility using electrogastrography (EGG).Results: Post-treatment, the patient showed high satisfaction and improvement in symptoms of nausea and vomiting. The following changes were observed in scores: GSRS: 23 to 19; VAS of nausea: 88 to 95; VAS of dyspepsia: 95 to 12; INVR: 13 to 1; NSS: 17 to 5; NDI-K: 107 to 78; and FD-QoL 84 to 27. We also found positive results in Channel 3 of EGG parameters, implying the improvement of gastric motility disorder.Conclusion: Korean medical treatment can be a therapeutic option for cyclic vomiting syndrome.
24
Jeong, Hae-in, Na-yeon Ha та Jin-sung Kim. "Spleen Daoyin Method (脾腸導引法) for Functional Dyspepsia Patients: A Case Report". Journal of Internal Korean Medicine 42, № 6 (2021): 1331–40. http://dx.doi.org/10.22246/jikm.2021.42.6.1331.
Full textAbstract:
A 42-year-old patient with functional dyspepsia had suffered from early satiation and postprandial fullness for 1 year despite Western medicine treatment. We treated her with the Spleen Daoyin method, along with acupuncture, moxibustion, and herbal medicine and scored her symptoms using a 4-point Functional Dyspepsia-related Quality of Life (4p-FD-QoL) questionnaire, the Gastrointestinal Symptom Rating Scale (GSRS), and a visual analogue scale (VAS). A 7-day Spleen Daoyin treatment decreased her 4p-FD-QoL score from 61 to 51, with a marked decrease in the emotional part (18 to 10). Her GSRS score did not change, but her bloating score decreased from 3 to 1. Her VAS score decreased from 6.6 to 4.3 for upper abdomen discomfort, but lower abdomen discomfort was unchanged. The patient showed high compliance and satisfaction with exercise therapy and reported no adverse events. Spleen Dayoin may be a useful therapy for functional dyspepsia, especially when accompanied by psychological problems.
25
Arita, Ryutaro, Takehiro Numata, Shin Takayama, et al. "Responder Analysis of Daikenchuto Treatment for Constipation in Poststroke Patients: A Subanalysis of a Randomized Control Trial." Journal of Evidence-Based Integrative Medicine 24 (January 1, 2019): 2515690X1988927. http://dx.doi.org/10.1177/2515690x19889271.
Full textAbstract:
A traditional Japanese medicine, daikenchuto (DKT), is used for treating abdominal bloating and pain with coldness. In modern medicine, it is used to treat postoperative intestinal dysfunction and ileus. We previously showed the effective improvement in functional constipation with DKT in poststroke patients. However, response prediction for the treatment has not been elucidated. We investigated the data from the prior trial (UMIN000007393) to predict the DKT treatment response. We assessed the efficacy of DKT for chronic constipation in poststroke patients. Neurogenic bowel dysfunction score (NBDS) and the Gastrointestinal Symptom Rating Scale–constipation subscale (GSRS-C) score were newly analyzed comparing the pre- and postintervention data after intake of 15 g of DKT extract granule daily for 4 weeks. Single and multiple regression analyses were performed to examine the correlations between the changes in NBDS, GSRS-C score, patient characteristics, clinical symptom score, gas volume in the gut, and serum calcitonin gene–related peptide level. The total NBDS and GSRS-C score were significantly reduced after DKT administration. The total NBDS, GSRS-C score, and gas volume score at baseline were significantly correlated with the change in these scores. Higher NBDS and GSRS-C scores and more gas volume in the gut may be possible predictors of response to DKT when treating constipation.
26
Nikolova, Dafina, Meri Trajkovska, Emilija Nikolovska Trpcevska, Vladimir Andreevski, Kalina Grivceva Stardelova, and Vesna Velic. "Evaluation of the Effects of Gastro Protect as an Alternative Medicine on Gastritis and Other Gastrointestinal Symptoms." PRILOZI 45, no. 1 (2024): 51–60. http://dx.doi.org/10.2478/prilozi-2024-0006.
Full textAbstract:
Abstract Introduction: The use of herbal medicine as a part of the Complementary and Alternative Medicine is increasing worldwide. Herbal remedies are used to better different conditions including gastritis. Material and Methods: We conducted a prospective randomized control clinical trial on a total sample of 72 patients with gastritis in order to examine the effects of the commercial herbal product Gastro Protect. After 6 weeks of conventional therapy the patients were divided into two groups with 36 patients each. As a continuation of the treatment, Group 1 received conventional therapy + Gastro Protect and Group 2 received conventional therapy + Placebo. We analyzed 14 selected gastrointestinal symptoms, five related to digestive problems, and nine related to stool and bowel problems. For assessing the selected symptoms we used seven point gastrointestinal symptom rating scale (GSRS). Results: The Gastro Protect group had a significantly lower GSRS score (better condition) compared to the Placebo group related to all five selected symptoms of digestive problems as: abdominal pain (p=0.0250), hunger pain (p=0.0276), nausea (p=0.0019), heartburn (p=0.00001), and acid reflux (p=0.0017). The Gastro Protect group, also had a significantly lower GSRS score (better condition) compared to the Placebo group related to three out of nine selected bowel symptoms: rumbling (p=0.0022), abdominal distension (p=0.0029), and gas or flatus (p=0.0039). Conclusion: Gastro protect was effective in treating gastritis and other gastrointestinal symptoms. It was safe for usage and showed almost no side effects. In our study, Gastro Protect reduced the examined gastric symptoms and related examined intestinal symptoms.
27
Bianco, Antonella, Isabella Franco, Alberto Rubén Osella, et al. "Physical Activity Reduction and the Worsening of Gastrointestinal Health Status during the Second COVID-19 Home Confinement in Southern Italy." International Journal of Environmental Research and Public Health 18, no. 18 (2021): 9554. http://dx.doi.org/10.3390/ijerph18189554.
Full textAbstract:
Due to the COVID-19 pandemic, in December 2020, the Italian government established a second home confinement during the Christmas holidays. These restrictions offered the opportunity to utilize a well-defined model for observing the consequences of lifestyle changes of healthy individuals. This study aimed at estimating in healthy subjects from Southern Italy the physical activity (PA), the presence and the severity of gastrointestinal (GI) symptoms, and the association between the possible worsening of GI health status and the PA levels. An adapted version of the International PA Questionnaire-short form (IPAQ-SF) and the Gastrointestinal Symptom Rating Scale (GSRS) were proposed through Google’s online survey platform in three different periods via WhatsAppTM to 499 healthy subjects (62% females) from Apulia (25%), Calabria (37%), and Campania (38%). Our results showed statistically significant changes during the home confinement: reduced energy expenditure (EE) among overweight subjects (−239.82, 95%CI −405.74; −73.89) or those who had high GSRS total score (−1079.54, 95%CI −2027.43; −131.66). An increase in GSRS total score was observed in overweight subjects, reaching statistical significance in those from Campania. Our study supports the importance of PA to reduce health risks, including those related to the possible onset of GI tract diseases.
28
Barkhatov, I. V. "Role of quality of life estimation in early diagnosis of abdominal angina." Kazan medical journal 94, no. 3 (2013): 406–8. http://dx.doi.org/10.17816/kmj2195.
Full textAbstract:
Aim. To assess the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire as an ambulatory screening test for early diagnosis of abdominal angina. Methods. An assessment of abdominal symptoms severity and quality of life was performed using the GSRS questionnaire in 110 patients with abdominal angina. No sings of abdominal angina and no vascular abnormalities were found at Doppler sonography in 39 (35.5%) of patients (main group). In 71 (64.5%) patients distributed to the second group signs of insufficient blood flow (including vascular wall calcification and thickening, medium and small arteries compression and narrowing up to 40-70%, and inadequate blood flow after exercise. Results. There were no statistically significant differences found in prevalence of abdominal pain, reflux and diarrhea between two groups. Dyspepsia was noted in 29 (74.4%) patients of first group and in 71 (100%) patients of the second group. Average GSRS scores were 3.67±0.51 and 5.07±0.32 accordingly in those patients. Constipation was present in 16 (41%) patients of first group and in 54 (76.1%) patients of the second group, with the GSRS score 1.33±0.31 and 3.04±0.32 accordingly in those patients. Average total GSRS score was significantly higher in patients with abdominal angina - 13.51±0.84 points versus 9.94±1.13 in patients without signs of abdominal angina on Doppler sonography. Conclusion. The use of GSRS questionnaire allows to detect syndromes characteristic for abdominal angina.
29
Rostami Ravari, Mohammad Arash, Shahram Vaziri, Mahdireza Sarafraz, and Amin Rafiepoor. "The Impact of Intensive Short-Term Dynamic Psychotherapy (ISTDP) on Psychological Capacity, Anxiety Severity, and Functional Gastrointestinal Disorders in Psychosomatic Patients with Gastrointestinal Symptoms." International Journal of Education and Cognitive Sciences 5, no. 2 (2024): 101–11. https://doi.org/10.61838/kman.ijecs.5.2.12.
Full textAbstract:
Purpose: The present study aimed to investigate the impact of Intensive Short-Term Dynamic Psychotherapy (ISTDP) on psychological capacity, anxiety severity, and functional gastrointestinal disorders in psychosomatic patients with gastrointestinal symptoms. Methodology: This research is applied in nature and utilized a quasi-experimental pretest-posttest design with a control group. The statistical population consisted of patients with gastrointestinal functional disorders who sought treatment for anxiety at the Bojika Counseling Center located in District 3 of Tehran in 2020. A sample of 16 participants was selected based on previous research and through purposive voluntary sampling. The sample was randomly assigned to experimental and control groups (8 participants per group). Participants were assessed before and after the intervention using the Beck Anxiety Inventory, the Gastrointestinal Symptom Rating Scale (GSRS), and the Ego Strength Scale. The experimental group underwent 15 sessions of ISTDP, each lasting 90 minutes, while the control group did not receive any intervention. Findings: Results from the simple mixed factorial design indicated that ISTDP was effective in reducing anxiety and gastrointestinal symptoms and in enhancing ego strength in psychosomatic patients with gastrointestinal symptoms in both the short-term (posttest) and long-term (follow-up) (P < 0.05).
30
Salamadze, Olha, and Liliia Babinets. "Assessment of the Quality of Life of Patients with Comorbidity of Hypothireosis and Chronic Pancreatitis." Family Medicine. European Practices, no. 1 (February 28, 2023): 57–59. https://doi.org/10.30841/2786-720X.1.2023.277484.
Full textAbstract:
Today, comorbidity has been recognized as a global problem of modern medicine around the world. The combined pathology of the thyroid gland and pancreas requires constant search and improvement of an individual approach to the treatment of patients and can improve large-scale socio-economic consequences. The article presents the analysis of quality of life (QL) of patients with comorbidity of hypothyroidism and chronic pancreatit is (CP). <strong>Materials and methods.</strong> The study included 62 inpatient patients with hypothyroidism and concomitant CP, who were treated at the gastroenterology center of the Yuriy Semeniuk Rivne Regional Clinical Hospital. The comparison group involved 48 patients with isolated CP. GSRS (Gastrointestinal Symptom Rating Scale) was used to evaluate the severity of gastroenterological symptoms and QL. <strong>Results.</strong> Analyzing the data of the GSRS questionnaire, it was found that in patients with hypothyroidism with concomitant CP, reflux, pain and dyspeptic syndromes were the most common clinical manifestations (p>0.05). According the GSRS questionnaire results, the clinical course of patients with the hypothyroidism was complicated by the comorbidity of the CP, namely: on the scale of gastric reflux – by 48.57 %, on a scale of dyspepsia – by 35.84 %, diarrhea – by 26.94 %, constipation – by 19.93 %, abdominal pain – by 40.81 %. <strong>Conclusions.</strong> As a result of the study, the lower level QL in patients with hypothyroidism with concomitant chronic pancreatitis (CP) was established compared to the isolated course of CP. It was determined that the comorbidity of hypothyroidism and CP leads to a complication of the clinical condition of patients.
31
Vikram, Baburao, Neetu Rawal, and Sunil Gupta. "Efficacy and safety of Neemint capsules in an open label single arm trial of patients with gastrointestinal disorders." International Journal of Research in Medical Sciences 10, no. 5 (2022): 1176. http://dx.doi.org/10.18203/2320-6012.ijrms20221192.
Full textAbstract:
Anti-inflammatory drugs which are commonly used medication in gastrointestinal (GI) disorder worsen symptoms and increasing impend need of better treatment method for the disease. Neemint capsules composed of polyherbal formulation of neem oil and peppermint oil. We conducted this study to assess the efficacy and safety of Neemint capsules in patients with gastrointestinal disorders including irritable bowel syndrome. We conducted an open label clinical study of 15 patients (mean age, 35.2±14.26 years; 86.6% males) with two or more GI symptoms. Patients were given Neemint capsule of 500 mg (350 mg of neem oil+150 mg of peppermint oil) as per each schedule visit. The primary endpoint was change in gastrointestinal symptom rating scale (GSRS-IBS). Secondary endpoints included monitoring of AE and SAE, IBS-quality of life questionnaire and change in subject’s global assessment of symptoms. The overall GSRS score improvement was found to be 64.23%. The IBS-QOL scores also indicated 57.2% increase in the quality of life of the study subject. The mean global assessment of symptoms (diarrhoea, constipation, abdominal pain, nausea vomiting and bloating) score recorded was 0. All results were significant at p<0.05. In this study we found that Neemint capsules is highly efficacious in the treatment of IBS and GI symptoms and it is also well-tolerated and safe in study subjects (n=15) having complaints of IBS and GI disturbances.
32
Vikram, Baburao, Neetu Rawal, and Sunil Gupta. "Efficacy and safety of Neemint capsules in an open label single arm trial of patients with gastrointestinal disorders." International Journal of Research in Medical Sciences 10, no. 5 (2022): 1176. http://dx.doi.org/10.18203/2320-6012.ijrms20221192.
Full textAbstract:
Anti-inflammatory drugs which are commonly used medication in gastrointestinal (GI) disorder worsen symptoms and increasing impend need of better treatment method for the disease. Neemint capsules composed of polyherbal formulation of neem oil and peppermint oil. We conducted this study to assess the efficacy and safety of Neemint capsules in patients with gastrointestinal disorders including irritable bowel syndrome. We conducted an open label clinical study of 15 patients (mean age, 35.2±14.26 years; 86.6% males) with two or more GI symptoms. Patients were given Neemint capsule of 500 mg (350 mg of neem oil+150 mg of peppermint oil) as per each schedule visit. The primary endpoint was change in gastrointestinal symptom rating scale (GSRS-IBS). Secondary endpoints included monitoring of AE and SAE, IBS-quality of life questionnaire and change in subject’s global assessment of symptoms. The overall GSRS score improvement was found to be 64.23%. The IBS-QOL scores also indicated 57.2% increase in the quality of life of the study subject. The mean global assessment of symptoms (diarrhoea, constipation, abdominal pain, nausea vomiting and bloating) score recorded was 0. All results were significant at p<0.05. In this study we found that Neemint capsules is highly efficacious in the treatment of IBS and GI symptoms and it is also well-tolerated and safe in study subjects (n=15) having complaints of IBS and GI disturbances.
33
Sachin Baburao Mulik, Kriti Soni, and Gayatri Pramod Ganu. "Clinical validation of de-stress and happy gut powder for stress reduction and gut health improvement." World Journal of Biology Pharmacy and Health Sciences 21, no. 2 (2025): 247–57. https://doi.org/10.30574/wjbphs.2025.21.2.1057.
Full textAbstract:
Introduction: Chronic stress and digestive disorders represent significant health challenges in modern society. This study investigates the potential of a novel herbal supplement, De-Stress & Happy Gut Powder, in addressing psychological stress and gastrointestinal symptoms through a comprehensive, natural approach. Materials and Methods: A single-arm, open-label clinical study was conducted with 30 participants (18 males, 12 females) aged 20-40 years. Participants consumed one sachet of De-Stress & Happy Gut Powder daily for 30 days. Assessments included the Perceived Stress Scale (PSS), Gastrointestinal Symptom Rating Scale (GSRS), comprehensive blood tests, and vital sign measurements. Results: The study demonstrated a statistically significant 57.54% reduction in perceived stress levels. Gastrointestinal symptom assessments revealed substantial improvements across multiple parameters, including upper abdominal pain, heartburn, acid reflux, and bowel-related symptoms. Hematological investigations showed statistically significant increases in white blood cell count, red blood cell count, and hematocrit, though these were not clinically significant. Adverse events were observed in 23.33% of participants and were not related to the investigational product. Conclusion: De-Stress & Happy Gut Powder demonstrates promising potential in simultaneously addressing stress and gastrointestinal health through a natural, holistic approach. Further randomized, controlled trials are recommended to validate these preliminary findings.
34
Melashchenko, Sergii G., Iryna G. Paliy, Serhii V. Zaika, and Anurag Krishna. "PREVALENCE OF GASTROINTESTINAL SYMPTOMS AMONG ENGLISH-SPEAKING STUDENTS IN THE CONTEXT OF EXPOSURE TO LEADING RISK FACTORS." Clinical and Preventive Medicine, no. 3 (March 20, 2025): 104–12. https://doi.org/10.31612/2616-4868.3.2025.14.
Full textAbstract:
Introduction. Hypodynamia and associated obesity, depression, and anxiety are recognized risk factors for numerous diseases of the digestive tract. Studying their impact on the young population is a particularly urgent task, given the spread of online learning and the increase in psychological stress induced by the Russian military invasion of Ukraine in recent years. Aim. To study the influence of the above-mentioned risk factors on the appearance of the gastrointestinal symptoms. Materials and methods. A survey of 208 English-speaking medical students was performed. It included 3 questionnaires: Gastrointestinal Symptom Rating Scale (GSRS), International Physical Activity Questionnaire (IPAQ), and Hospital Anxiety and Depression Scale (HADS). Body weight, height, alcohol consumption, and smoking habits were also estimated. Results. 62% of students reported troublesome complaints greater than “minor discomfort” at least in one of the GSRS clusters. The total number of points on the GSRS, as well as in the clusters “abdominal pain” (AP), “reflux” (RS), “indigestion” (IS), “diarrhea” (DS) and “constipation” (CS), were significantly correlated with the severity of anxiety (r = 0.14 to 0.19) but not depression. Alcohol consumption, expressed in three stipulated levels, also increased scores in all clusters except RS and CS. A higher MET-parameter of IPAQ was associated with reduced symptoms in the RS cluster. Only 36.5% of students didn’t experience anxiety, and 24.5% didn’t experience depression. Seasonality of these syndromes was observed: the average anxiety score (Mean±SEM) in winter was 9.10±0.23 points versus 7.20±0.56 points in summer; for depression, it was 12.36±0.18 versus 6.21±0.48, respectively (p<0.05). To identify the risk factors of gastrointestinal symptoms, a logistic regression analysis was performed using four predictor variables that demonstrated a significant association in preliminary assessments. Conclusions. Independent predictors (risk factors) of troublesome gastrointestinal symptoms in the studied population include intense anxiety (HADS score), low levels of physical activity (MET parameter), female gender, and the winter season. Depression is associated with concomitant anxiety and the winter season but is not directly related to gastrointestinal complaints.
35
P. V., Kishan, Raunak J. Soman, Dhruv Soman, and Sarath Chandra Gorantla. "Individual component analysis of gastrointestinal symptom rating scale for irritable bowel syndrome in irritable bowel syndrome patients treated with Bacillus coagulans SNZ 1969: additional findings from a randomized, double-blind, placebo-controlled study." International Journal of Basic & Clinical Pharmacology 14, no. 2 (2025): 290–94. https://doi.org/10.18203/2319-2003.ijbcp20250491.
Full textAbstract:
This study evaluated the therapeutic efficacy of Bacillus coagulans SNZ 1969 (B. coagulans SNZ 1969) in patients with constipation-predominant irritable bowel syndrome (IBS-C) and diarrhea-predominant IBS (IBS-D). We conducted a randomized, double-blind, placebo-controlled trial in 80 patients (40 IBS-C, 40 IBS-D) who received either B. coagulans SNZ 1969 (500 million CFU) or placebo twice daily for 60 days. Assessments were performed at baseline and on days 30, 60, and 75. Here we present the additional findings of the individual components of Gastrointestinal Symptom Rating Scale for IBS (GSRS-IBS). Results demonstrated significant reductions in all individual components of GSRS-IBS (abdominal pain, bloating, constipation, diarrhea, and satiety) in both IBS-C and IBS-D patients treated with B. coagulans SNZ 1969 compared to placebo. In conclusion, B. coagulans SNZ 1969 found to be an effective therapeutic option for IBS, demonstrating broad efficacy across multiple symptom domains.
36
Paliy, I. G., S. V. Zaika, K. V. Ksenchyna, and I. V. Chernova. "Validation of the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire for Ukrainian-speaking population in Vinnytsia region." Modern Gastroenterology, no. 4 (December 16, 2024): 30–37. https://doi.org/10.30978/mg-2024-4-30.
Full textAbstract:
Gastroesophageal reflux disease (GERD) is one of the most common pathologies of the digestive system. The main complaint is heartburn. The prevalence of gastroesophageal reflux disease is expected to remain high and even increase. Objective — to translate and adapt the Frequency Scale for the Symptoms of GERD (FSSG) questionnaire into Ukrainian and validate its use among the Ukrainian‑speaking population in Vinnytsia region as a screening tool for gastroesophageal reflux disease. Materials and methods. The process of cross‑cultural adaptation of the English version was carried out in accordance with the recommendations of the International Society for Pharmacoeconomics and Outcomes Research. We interviewed 42 people with complaints of diseases of the digestive system using the FSSG and Gastrointestinal Sуmptom Rating Scale (GSRS) questionnaires. The comprehensibility and complexity of the Ukrainian‑language version of the FSSG was evaluated on a 4‑point Likert scale, reliability — by the test‑retest method with an interval of three days, validity — by comparing the results of the questionnaires. Results. Comparing the results of the FSSG and GSRS questionnaires, a statistically significant correlation of moderate strength was found between FSSG reflux symptom scores and GSRS reflux syndrome scores (0.59; 95% CI: 0.35 to 0.76) and between total FSSG score and GSRS dyspeptic syndrome score (0.5; 95% CI: 0.23 to 0.69). The comprehensibility and complexity index corresponds to 1.0. Reliability was assessed using the test‑retest method with an interval of 3 days, the intraclass correlation coefficient between the results was 0.81 (95% CI: from 0.68 to 0.89). According to the results of the internal consistency analysis of the FSSG questionnaire, the Cronbach’s alpha coefficient was 0.7 at an acceptable level >0.7. Although the questionnaire does not provide definitive information to verify the diagnosis, this method is widely used in modern medical practice to identify groups of patients with typical and atypical symptoms that are subject to further examination. Conclusions. The FSSG is a screening method for gastroesophageal reflux disease in patients with symptoms typical of the upper gastrointestinal tract that has demonstrated reliability and validity.
37
Hashimoto, Yoshitaka, Genki Kobayashi, Noriyuki Kitagawa, Hiroshi Okada, Masahide Hamaguchi, and Michiaki Fukui. "Protocol of efficacy of bifidobacteria intake on gastrointestinal symptoms in symptomatic type 2 diabetes mellitus patients in abdominis: An open-label, randomized controlled trial (Binary STAR study)." PLOS ONE 19, no. 1 (2024): e0295998. http://dx.doi.org/10.1371/journal.pone.0295998.
Full textAbstract:
Background This randomized, parallel-group study aims to investigate the effects of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the symptoms of diarrhea or constipation in patients with type 2 diabetes mellitus (T2DM). Methods This study will examine 100 patients with T2DM who suffering from symptoms of diarrhea or constipation. Eligible patients will be randomly assigned 1:1 to two groups (group A, BBG9-1 group; group B, control group), after the baseline examination. Patients assigned to group A will receive probiotic BBG9-1 oral administration along with their current treatment for 12 weeks, and patients assigned to group B will continue the current treatment for 12 weeks without probiotic BBG9-1 oral administration. Subsequently, examinations similar to the baseline examinations will be performed. The primary endpoint will be a change in the Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to week 12. Secondary endpoints will include the following: change and percent change in parameters such as GSRS subdomain scores, fecal properties/Bristol stool form scale, defecation frequency, biomarkers, gut microbiota, and macronutrients and factors that affect GSRS total score or constipation/diarrhea subdomain scores from baseline to week 12. Discussion The results of this study will clarify the utility of probiotic BBG9-1 in the treatment of diarrhea or constipation in patients with T2DM. Trial registration jRCTs051220127.
38
Armstrong, David, Sander JO Veldhuyzen van Zanten, Sharon A. Chung, et al. "Validation of a Short Questionnaire in English and French for Use in Patients with Persistent Upper Gastrointestinal Symptoms Despite Proton Pump Inhibitor Therapy: The Pass (Proton Pump Inhibitor Acid Suppression Symptom) Test." Canadian Journal of Gastroenterology 19, no. 6 (2005): 350–58. http://dx.doi.org/10.1155/2005/569368.
Full textAbstract:
BACKGROUND: The management of persistent symptoms during acid suppression therapy in patients with gastroesophageal reflux disease or dyspepsia might be improved if patient-physician communication regarding the presence and character of these persistent symptoms were facilitated.AIM: To validate a short, simple questionnaire (the Proton pump inhibitor [PPI] Acid Suppression Symptom [PASS] test), in English and French, to identify patients with persistent acid-related symptoms during PPI therapy and document their response to a change in therapy.METHODS: Patients with persistent acid-related symptoms on PPI therapy were interviewed to produce a draft, five-item questionnaire; content validity was evaluated by focus groups comprising English- and French-speaking patients. Psychometric validity was subsequently evaluated in a multicentre, family practice-based study of English- and French-speaking patients with persistent acid-related upper gastrointestinal symptoms despite PPI therapy. The PASS test, Global Overall Symptom scale, Gastrointestinal Symptom Rating Scale (GSRS), Quality of Life in Reflux and Dyspepsia questionnaire and Reflux Disease Questionnaire were completed at baseline and repeated after one week while patients continued their original PPI therapy. All patients then received esomeprazole 40 mg once daily for four weeks, after which all questionnaires and an evaluation of overall treatment effect were completed.RESULTS: Content validity was established in 20 English- and 16 French-speaking patients. Psychometric validation in 158 English- and 113 French-speaking patients revealed good-to-excellent test-retest reliability coefficients: 0.76 for English; 0.68 for French. For construct validity, the PASS test showed moderate-to-high correlation with the GSRS scale (0.51 for English; 0.43 for French). After four weeks of therapy, the PASS test score fell to zero in 30% of English- and 33% of French-speaking patients, while the Global Overall Symptom score fell to one (no symptoms) in 32% of patients (English- and French-speaking); the PASS test demonstrated good responsiveness in comparison with the GSRS, Reflux Disease Questionnaire and Quality of Life in Reflux and Dyspepsia questionnaire.CONCLUSION: The five-item PASS test is a valid tool for the evaluation of persistent acid-related symptoms in patients receiving PPI therapy. It demonstrates good content validity, test-retest reliability, responsiveness and construct validity in both English and French forms. The PASS test is a simple, clinically applicable tool for the identification of patients with persistent acid-related symptoms during therapy and the assessment of their responses to a change in therapy.
39
Pagoldh, Jenny, David Lundgren, Ole B. Suhr, and Pontus Karling. "Irritable bowel syndrome-like symptoms in treated microscopic colitis patients compared with controls: a cross-sectional study." Gastroenterology Report 8, no. 5 (2019): 374–80. http://dx.doi.org/10.1093/gastro/goz069.
Full textAbstract:
Abstract Background The prevalence of irritable bowel syndrome (IBS)-like symptoms is high in untreated patients with microscopic colitis (MC), but there is uncertainty of the prevalence of IBS-like symptoms in treated patients. We assessed the degree of IBS-like symptoms in patients with MC in comparison to control subjects, and investigated the association between IBS-like symptoms and faecal calprotectin (FC) in MC patients. Methods Patients with an established MC diagnosis (n = 57) were compared to sex- and age-matched controls (n = 138) for scores in the GSRS-IBS (Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome) and HADS (Hospital Anxiety Depression Scale). In MC patients, an FC level was simultaneously analysed. Results The median interval from MC diagnoses to the time the subjects participated in the study was 5.5 years (25th–75th percentiles; 4.5–9.5 years). The total GSRS-IBS score, subscores for abdominal pain, bloating, and diarrhoea were significantly higher in MC patients compared to controls (all P &lt; 0.001). There was a significant correlation between FC levels and reported bowel frequency (P = 0.023), but there was no correlation between FC levels and GSRS-IBS scores. Patients with MC had significantly higher scores on anxiety (HADS-A) (P &lt; 0.001) and used more selective serotonin-reuptake-inhibitor drugs (P = 0.016) than the control subjects. However, only the control subjects (not the patients with MC) showed significant correlations between GSRS-IBS scores and HADS scores. Conclusions Patients with MC reported more IBS-like symptoms and anxiety than control subjects but neither FC levels nor symptoms of affectivity were significantly correlated with IBS-like symptoms.
40
Chang, N., M. Khaouli, D. Armstrong, and M. Pinto-Sanchez. "A80 SELF-COMPLETED QUESTIONNAIRES IDENTIFY SYMPTOMS IN A PROPORTION OF PATIENTS WITH CELIAC DISEASE CONSIDERED ASYMPTOMATIC DURING CLINICAL VISITS." Journal of the Canadian Association of Gastroenterology 7, Supplement_1 (2024): 55–56. http://dx.doi.org/10.1093/jcag/gwad061.080.
Full textAbstract:
Abstract Background Patients with celiac disease (CeD) often experience symptoms despite adhering strictly to a gluten-free diet, and novel therapies are under development to help symptom management. However, recruitment for clinical trials [DA1] can be challenging, as screening is often based on symptoms reported to the physician during a clinic visit. However, symptoms reported by patients during clinic visits may not be an accurate reflection of the true extent of the symptoms. Aims To assess whether gastrointestinal (GI) symptoms reported by patients to physicians during a clinic visit differ from those self-reported in questionnaires on the same day. Methods A retrospective chart review of patients enrolled in the celiac registry (HiREB #5415, #16758) was performed. We included adult patients enrolled in our celiac registry from January 2021 to August 2023. We collected data on demographics such as age, sex, gender, time since CeD diagnosis (early diagnosis defined as within 2 years versus late diagnosis as greater than 2 years), CeD serology (TTG, DGP, EmA), in addition to GI symptoms 1) reported to the physician during the clinic visit, and 2) recorded on a validated questionnaire (Gastrointestinal Symptoms Rating Scale - GSRS) completed on the same day. A GSRS score greater than 30 for overall GI symptoms and a score greater than 2 for any individual symptom was considered symptomatic. Results We reviewed a total of 174 patient charts that met the inclusion criteria during the defined time period. Overall, 107 patients reported symptoms during the clinic visit; of the remaining 67 patients who did not report symptoms at the clinic visit, 29 (43.2%) were identified as symptomatic by the GSRS. Compared to the clinical history, the GSRS identified higher rates of abdominal pain (77% vs 12.6%, p=0.0001), diarrhea (44.8% vs 11.4%, p=0.0001), bloating (87.3% vs 30.5%, p=0.0001), GERD (55.1% vs 5.1%, p=0.0001), constipation (57.4% vs 15.2%, p=0.0001) and nausea (56.3% vs 10.8, p=0.0001). There were no differences in responses between clinical visits and GSRS when subgrouped by gender, age, time since diagnosis or disease activity. Conclusions Self-reported questionnaires identify a subgroup of patients with celiac disease who reported GI symptoms when completing a validated questionnaire despite reporting no symptoms during a clinic visit. Screening patients for clinical research studies is often based on symptoms reported to the physician during the clinical visit, and therefore this has direct implications for research recruitment in gastroenterology clinical trials. Funding Agencies None
41
Kim, Yu-bin, Hyonjun Chun, Seong-hyeon Jeon, et al. "A Case of Non-small Cell Lung Cancer Who Complained of Abdominal Pain After Chemotherapy Improved by Complex Korean Medicine Treatment Including <i>Gaewool-whadam-jeon</i> - Case Report." Journal of Internal Korean Medicine 45, no. 6 (2024): 1360–73. https://doi.org/10.22246/jikm.2024.45.6.1360.
Full textAbstract:
Objective: This study aimed to evaluate the effectiveness of complex Korean medicine treatment for abdominal pain after chemotherapy.Methods: A 69-year-old male diagnosed with lung cancer complained of abdominal pain after chemotherapy and was hospitalized for 32 days. The patient received complex Korean medicine treatments, including acupuncture, along with herbal medicine, including <i>Gaewool-whadam-jeon</i>.Results: After 32 days of treatment, abdominal pain decreased on the Gastrointestinal Symptom Rating Scale (GSRS) (from 18 to 2), the numeric rating scale (NRS) (8 to 3), and the visual analog scale (VAS) (10 to 3). The quality of life improved in Version 2 of the 36-item Short-Form Health Survey, the physical component summary (PCS) from 20 to 61.9, and the mental component summary (MCS) from 15.9 to 50.9. A three-month follow-up after discharge confirmed continued improvement in symptoms with no significant side effects.Conclusion: This study suggests that complex Korean medicine treatment may be effective for managing abdominal pain after chemotherapy.
42
Tryapitsyn, A. V., and V. A. Apryatina. "Use of alpha-glutamyl-tryptophan in patients with chronic atrophic autoimmune gastritis: interim study results." Russian Journal of Evidence-Based Gastroenterology 14, no. 2 (2025): 5. https://doi.org/10.17116/dokgastro2025140215.
Full textAbstract:
Objective. To analyze clinical outcomes in patients over 18 years of age receiving alpha-glutamyl-tryptophan for autoimmune atrophic gastritis (AAG). Material and methods. Ten patients diagnosed with chronic AAG were enrolled and prescribed alpha-glutamyl-tryptophan («Regastim Gastro», oral gel powder). The study followed a prospective before-and-after design. After two of four planned therapy courses, interim results were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and a Likert scale evaluating treatment satisfaction. Adverse events were monitored. Results. Based on the GSRS, four of nine patients reported significant symptom reduction (>10 points), two showed minor improvement (1—2 points), and three had no changes. According to the Likert scale, all patients noted some degree of improvement, with five indicating marked relief. One underweight female patient gained weight during therapy. Alpha-glutamyl-tryptophan had no adverse effect on the efficacy or dosing of concomitant medications. Two patients reported self-limiting diarrhea during the first two days of treatment, and one experienced mild, transient epigastric and periumbilical discomfort during the first five days. These effects resolved without intervention or treatment discontinuation. Conclusion. After two courses of alpha-glutamyl-tryptophan therapy, patients with autoimmune atrophic gastritis demonstrated good treatment tolerability, symptomatic improvement, enhanced quality of life, and no negative interactions with other medications.
43
Pilipovich, A. A., O. V. Vorob'eva, S. A. Makarov, and A. V. Kuchuk. "Effect of dopaminergic therapy on lacrimation in Parkinson's disease." Neurology, Neuropsychiatry, Psychosomatics 15, no. 6 (2023): 32–39. http://dx.doi.org/10.14412/2074-2711-2023-6-32-39.
Full textAbstract:
The prevalence of dry eye syndrome (DES) in Parkinson's disease (PD) reaches 87% and leads to impaired quality of life in many patients.Objective: to evaluate the lacrimal function and the effect of dopaminergic therapy in patients with PD.Material and methods: 43 patients with stage II–III PD according to Hoehn and Yahr (H&Y) receiving therapy with levodopa (n=17), amantadines (n=13) and dopamine receptor agonists (ADR) (n=28) were assessed using Schirmer's test (to estimate tear flow), sialometry, Unified Parkinson's Disease Rating Scale (UPDRSI-IV), Schwab and England Activities of Daily Living scale (Sch&En), the Parkinson’s Disease Questionnaire Summary Index (PDQ-39), the Mini Mental State Examination Scale (MMSE), the Non-Motor Symptom Questionnaire (NMSQ), the American Urological Association Symptom Scale (AUA), the Gastrointestinal Symptom Rating Scale (GSRS), the Bristol Stool Form Scale (BSFS).Results. Lacrimal insufficiency was found in 49% of patients. It occurred more frequently (χ2=9.546; p=0.003) in patients taking amantadine and correlated with the daily dose of amantadine (r-S=-0.359). It did not depend on the intake of ADR and levodopa and their doses but correlated with the UPDRS-IV score (r-S= -0.463), namely with the presence and duration of OFF-periods. Lacrimal insufficiency correlated with the Sch&En score (r-S=0.321) and non-motor parameters: UPDRSI (r-S =-0.302), NMSQ (r-S=-0.435), constipation domain of the GSRS (r-S=-0.362), BSFS (r-S=0.363). It was not related to age, gender, stage and duration of PD, motor symptoms of parkinsonism (assessed during the ON-phase) and was not related to salivation (although it was reduced in 39.5% of patients).Conclusion. Lacrimal insufficiency is observed in half of patients with stage II–III PD; it is related to the presence and duration of OFF-periods, the severity of other autonomic disorders and the use of amantadines, suggesting the role of dopamine dysregulation, neurodegeneration of autonomic centers and anticholinergic therapy in the development of DES in PD.
44
Salamadze, Olha, and Liliia Babinets. "Assessment of the Quality of Life of Patients with Comorbidity of Hypothireosis and Chronic Pancreatitis." Family medicine. European practices, no. 1 (February 28, 2023): 57–59. http://dx.doi.org/10.30841/2786-720x.1.2023.277484.
Full textAbstract:
Today, comorbidity has been recognized as a global problem of modern medicine around the world. The combined pathology of the thyroid gland and pancreas requires constant search and improvement of an individual approach to the treatment of patients and can improve large-scale socio-economic consequences. The article presents the analysis of quality of life (QL) of patients with comorbidity of hypothyroidism and chronic pancreatit is (CP). Materials and methods. The study included 62 inpatient patients with hypothyroidism and concomitant CP, who were treated at the gastroenterology center of the Yuriy Semeniuk Rivne Regional Clinical Hospital. The comparison group involved 48 patients with isolated CP. GSRS (Gastrointestinal Symptom Rating Scale) was used to evaluate the severity of gastroenterological symptoms and QL. Results. Analyzing the data of the GSRS questionnaire, it was found that in patients with hypothyroidism with concomitant CP, reflux, pain and dyspeptic syndromes were the most common clinical manifestations (p>0.05). According the GSRS questionnaire results, the clinical course of patients with the hypothyroidism was complicated by the comorbidity of the CP, namely: on the scale of gastric reflux – by 48.57 %, on a scale of dyspepsia – by 35.84 %, diarrhea – by 26.94 %, constipation – by 19.93 %, abdominal pain – by 40.81 %. Conclusions. As a result of the study, the lower level QL in patients with hypothyroidism with concomitant chronic pancreatitis (CP) was established compared to the isolated course of CP. It was determined that the comorbidity of hypothyroidism and CP leads to a complication of the clinical condition of patients.
45
AUFIERI, Mariana Cerne, Juliana Masami MORIMOTO, and Renata Furlan VIEBIG. "SEVERITY OF IRRITABLE BOWEL SYNDROME SYMPTOMS AND FODMAPS INTAKE IN UNIVERSITY STUDENTS." Arquivos de Gastroenterologia 58, no. 4 (2021): 461–67. http://dx.doi.org/10.1590/s0004-2803.202100000-84.
Full textAbstract:
ABSTRACT BACKGROUND: Irritable bowel syndrome (IBS) symptoms such as diarrhea, bloating and abdominal pain can reduce University student’s productivity and learning ability. One of the possible treatments for IBS is the temporarily exclusion of foods that have a high content of short-chain fermentable carbohydrates, the fermentable, oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). OBJECTIVE: This study aimed to assess University student’s intake of foods that are rich in FODMAPs, looking for possible associations with the severity of IBS symptoms. METHODS: A cross-sectional study was carried out, with undergraduate students from a private University in the city of São Paulo, Brazil, aged between 19 and 46 years old and that were enrolled in different courses and stages. Students were invited to participate and those who gave their formal consent were included in this research. A sociodemographic and lifestyle questionnaire was applied, in addition to the Gastrointestinal Symptom Rating Scale - GSRS. Students also responded a short Food Frequency Questionnaire, developed to investigate habitual FODMAPs intake of Brazilian adult population. Spearman’s correlation analysis between the student’s GSRS scores and the frequency of foods rich in FODMAPs intake were performed in SPSS v.21. RESULTS: Fifty-six students were interviewed, with mean age of 21.4 years old (SD=4.41), with a predominance of women (76.8%). The GSRS results showed that 58.9% of students felt minimal to moderate abdominal discomfort and 14.3% had moderately severe to very severe abdominal pain during the prior week to the interview. Besides abdominal pain, the gastrointestinal symptoms that were most reported by students were flatulence (98.2%), stomach rumbling (89.3%) and eructations (85.7%). Greater symptom severity was observed in women (P=0.004) and sedentary students (P=0.003). Regarding FODMAPs consumption, honey (P=0.04), chocolate (P=0.03) and milk table cream (P=0.001) intakes were positively correlated with the greater severity of symptoms. CONCLUSION: Although clinical diagnosis is necessary to establish IBS, 73.2% of the students presented minimal to very severe abdominal pain during the prior week. Female had sedentary students had greater severity of gastrointestinal symptoms. A low FODMAP diet, well oriented, could bring some symptoms relief to these University students.
46
Zhao, Wenjing, Yong Li, Ruijin Xie, et al. "Real-World Evidence for COVID-19 Delta Variant’s Effects on the Digestive System and Protection of Inactivated Vaccines from a Medical Center in Yangzhou, China: A Retrospective Observational Study." International Journal of Clinical Practice 2022 (August 19, 2022): 1–9. http://dx.doi.org/10.1155/2022/7405448.
Full textAbstract:
Background. Coronavirus disease 2019 (COVID-19) is rapidly disseminated worldwide, and it continues to threaten global public health. Recently, the Delta variant has emerged as the most dreaded variant worldwide. COVID-19 predominantly affects the respiratory tract, and studies have reported the transient effects of COVID-19 on digestive system function. However, the relationship between the severity of the Delta variant and digestive system function remains to be investigated. Additionally, data on the ability of the inactive Chinese vaccines (Sinovac or Sinopharm) to protect against the Delta variant or COVID-19-induced gastrointestinal symptoms in the real world are insufficient. Thus, the present retrospective observational study first attempted to use the total gastrointestinal symptom rating scale scores (GSRS) to quantify the possible changes in digestive system functions following the Delta variant infection in the early stage. In addition, the study discusses the potential of inactivated vaccines in preventing severe or critical symptoms or Delta variant-induced digestive system dysfunction. Methods. To evaluate the difference between mild illness group, moderate illness group, and severe or critical illness group, analysis of variance (ANOVA) was employed to compare the three groups' total gastrointestinal symptom rating scale scores (GSRS). A chi-squared test was used to compare the differences in the ratio of the abnormal biochemical measurements among the three groups first. Then, the percentage of the vaccinated population was compared among the three groups. Additionally, the ratio of the abnormal serum markers between the vaccinated and nonvaccinated cohorts was compared. A P value < 0.05 was considered statistically significant. Results. Significant differences were observed in the abnormal ratio of alanine aminotransferase (ALT), total bilirubin (TBIL), direct bilirubin (DBIL), lactate dehydrogenase (LDH), and Interleukin 6 (IL-6) ratio among the three groups ( P < 0.05 ). Additionally, no significant difference was observed in the abnormal serum markers ratio between day 14 and day 21 after treatment ( P > 0.05 ). A significant difference was observed in the total GSRS scores among the three groups and the ratio of the vaccinated population among the three groups ( P < 0.05 ). A significant difference was observed in the ratio of the abnormal serum ALT and AST levels between the vaccinated and nonvaccinated cohorts ( P < 0.05 ). Conclusions. In summary, serum AST, DBIL, LDH, and IL-6 levels are potential markers for distinguishing severe or critical patients in the early stage of the Delta variant infection. Additionally, changes in the levels of these serum makers are transient, and the levels can return to normal after treatment. Furthermore, severe gastrointestinal discomfort was significantly more prevalent in patients with severe or critical diseases and should thus be considered in patients diagnosed with Delta variant infection. Finally, inactivated vaccines may prevent severe or critical symptoms and Delta variant-induced liver dysfunction. Vaccination programs must be promoted to protect public health.
47
Chahal-Kummen, M., O. B. K. Salte, S. Hewitt, et al. "Health benefits and risks during 10 years after Roux-en-Y gastric bypass." Surgical Endoscopy 34, no. 12 (2020): 5368–76. http://dx.doi.org/10.1007/s00464-019-07328-2.
Full textAbstract:
Abstract Background Long-term evaluations 10 years after Roux-en-Y gastric bypass (RYGB) are limited. We report the development in weight and cardiovascular risk factors during 10 years after laparoscopic RYGB, with evaluation of gastrointestinal symptoms and quality of life (QoL) at 10-year follow-up. Methods We performed a prospective longitudinal cohort study. Patients operated with laparoscopic RYGB from May 2004 to November 2006 were invited to 10-year follow-up consultations. Gastrointestinal Symptom Rating Scale (GSRS) questionnaire and two QoL questionnaires were used for analyses of gastrointestinal symptoms and QoL. Results A total of 203 patients were operated; nine (4.4%) died during follow-up. Of 194 eligible patients, 124 (63.9%) attended 10-year follow-up consultations. Percent excess weight loss (%EWL) and percent total weight loss (%TWL) at 10 years were 53.0% and 24.1%, respectively. %EWL > 50% was seen in 53.2%. Significant weight regain (≥15%) from 2 to 10 years was seen in 63.3%. Remission rates of type 2 diabetes, dyslipidemia, and hypertension were 56.8%, 46.0%, and 41.4%, respectively. Abdominal operations beyond 30 days after RYGB were reported in 33.9%. Internal hernia and ileus (13.7%) and gallstone-related disease (9.7%) were the most common causes. Vitamin D deficiency (<50nmol/L) was seen in 33.3%. At 10 years, bothersome abdominal pain and indigestion symptoms (GSRS scores ≥3) were reported in 42.9% and 54.0%, respectively, and were associated with low QoL. Conclusion We observed significant weight loss and remission of comorbidities 10 years after RYGB. Significant weight regain occurred in a substantial subset of patients. Gastrointestinal symptoms were common and negatively impacted QoL.
48
Yamada, Naruomi, Kyosuke Kobayashi, Akika Nagira, et al. "The Beneficial Effects of Regular Intake of Lactobacillus paragasseri OLL2716 on Gastric Discomfort in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Study." Nutrients 16, no. 18 (2024): 3188. http://dx.doi.org/10.3390/nu16183188.
Full textAbstract:
We investigated the effects of Lactobacillus paragasseri OLL2716 on gastrointestinal symptoms in healthy adults with gastric complaints. In this randomized, double-blind, placebo-controlled trial, 174 healthy Japanese adults were randomly assigned to an OLL2716 or placebo group, and each group consumed 85 g of yogurt containing L. paragasseri OLL2716 or placebo yogurt daily for 12 weeks. The primary endpoint was the change in gastric symptoms from baseline as per the participants’ questionnaires at 6 and 12 weeks. The secondary endpoints were changes from baseline in the short-form Nepean Dyspepsia Index (SF-NDI), the Gastrointestinal Symptom Rating Scale (GSRS), and the Council on Nutrition Appetite Questionnaire-Japanese (CNAQ-J) scores at 6 and 12 weeks. The primary endpoint data showed that the changes in “epigastric pain” at 6 and 12 weeks were significantly decreased in the OLL2716 group compared with those in the placebo group. Additionally, the changes in “epigastric pain syndrome-like symptoms” were significantly decreased in the OLL2716 group compared with those in the placebo group at 6 weeks. The SF-NDI items that improved at 6 weeks were “irritable, tense, or frustrated”, “enjoyment of eating or drinking”, and “tension”, which are sub-scales related to mental stress. The items “Over-all” in the GSRS and “feeling hungry” in the CNAQ-J significantly improved in the OLL2716 group compared with the placebo group at 12 weeks. The results suggest that regular intake of L. paragasseri OLL2716 may improve both gastric discomfort and mental stress in healthy adults with gastric complaints, such as postprandial fullness or early satiety.
49
Graziani, Cristina, Lucrezia Laterza, Claudia Talocco, et al. "Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study." Journal of Personalized Medicine 12, no. 6 (2022): 1005. http://dx.doi.org/10.3390/jpm12061005.
Full textAbstract:
Recurrent cystitis (RC) is a common disease, especially in females. Anatomical, behavioral and genetic predisposing factors are associated with the ascending retrograde route, which often causes bladder infections. RC seems to be mainly caused by agents derived from the intestinal microbiota, and most frequently by Escherichia coli. Intestinal contiguity contributes to the etiopathogenesis of RC and an alteration in intestinal permeability could have a major role in RC. The aim of this pilot study is to assess gut microbiome dysbiosis and intestinal permeability in female patients with RC. Patients with RC (n = 16) were enrolled and compared with healthy female subjects (n = 15) and patients with chronic gastrointestinal (GI) disorders (n = 238). We calculated the Acute Cystitis Symptom Score/Urinary Tract Infection Symptom Assessment (ACSS/UTISA) and Gastrointestinal Symptom Rating Scale (GSRS) scores and evaluated intestinal permeability and the fecal microbiome in the first two cohorts. Patients with RC showed an increased prevalence of gastrointestinal symptoms compared with healthy controls. Of the patients with RC, 88% showed an increased intestinal permeability with reduced biodiversity of gut microbiota compared to healthy controls, and 68% of the RC patients had a final diagnosis of gastrointestinal disease. Similarly, GI patients reported a higher incidence of urinary symptoms with a diagnosis of RC in 20%. Gut barrier impairment seems to play a major role in the pathogenesis of RC. Further studies are necessary to elucidate the role of microbiota and intestinal permeability in urinary tract infections.
50
Satya, Prakash Singh, Kumari Asha, and Kumar Sushil. "A Hospital-Based Assessment of the Efficacy and Acceptability of Pomegranate Effervescent Granules (PEGS) in Dyspeptic Patients." International Journal of Current Pharmaceutical Review and Research 15, no. 06 (2023): 371–78. https://doi.org/10.5281/zenodo.12605538.
Full textAbstract:
AbstractAim: This study aimed to assess the efficacy and acceptability of pomegranate effervescentgranules (PEGs) in dyspeptic patients.Material & Methods: This hospital-based study was conducted by the Department ofPharmacology, DMCH, Laheriasarai, Darbhanga, Bihar, India for nine months. The granules,prepared from peel extract of pomegranate, were made available in sachets of 2.5 g with doseof, 1 sachet dissolved in 200 ml (1 cup) of water, twice a day after meals for 28 days.Gastrointestinal Symptom Rating Scale (GSRS) scores to assess symptoms of acid pepticdisorders at day 0, 15, and 29 along with the taste of formulation were the main studyoutcomes.Results: The results showed that in the Punica granatum treatment group with a dose above500 mg/kg, Ulcer Area (mm2) was 126.44±1.26 and Ulcer Inhibition % was 85.65. In thePunica granatum treatment group with a dose of 250 mg/ kg Ulcer Area (mm2) was455.60±8.48 and Ulcer Inhibition % 42.83. In the omeprazole treatment group, Ulcer Area(mm2) was 620.20±11.49 and Ulcer Inhibition was 25.55. While in the control group UlcerArea (mm2) was 822.00 ± 25.75 and Ulcer Inhibition % 15.75 And this Ulcer Inhibition % inthe Punica granatum treatment groups was significant compared to the omeprazole treatmentgroup and the control group (P=0.0001). The highest zone of inhibition (13 mm) wasrecorded against Y. enterocolitica and S. enterica compared with selected studied bacteria.The second highest zone of inhibition was 10.5 mm observed against B. cereus.Conclusion: PEGs proved to be palatable, patient-friendly, safe, and efficacious in resolvingsymptoms of dyspepsia in acid peptic disorders